This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
==== August 2015 norovirus ==== A norovirus outbreak occurred in August 2015 at a Simi Valley, California, location, ultimately affecting more than 200 people. Ventura County health inspectors found health violations during inspections following the outbreak. In January 2016, a federal grand jury issued a subpoena as part of a criminal investigation into the outbreak.
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders (ASDs) and/or other pervasive developmental disorders (PDDs) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in October 2024. It is likely to become outdated with time.
=== Microarray-based methods === Microarray-based methods are a logical extension of the technologies available to analyze bisulfite-treated DNA to allow for genome-wide analysis of methylation. Oligonucleotide microarrays are designed using pairs of oligonucleotide hybridization probes targeting CpG sites of interest. One is complementary to the unaltered methylated sequence, and the other is complementary to the C-to-U-converted unmethylated sequence. The probes are also bisulfite-specific to prevent binding to DNA incompletely converted by bisulfite. The Illumina Methylation Assay is one such assay that applies the bisulfite sequencing technology on a microarray level to generate genome-wide methylation data.
Sources: en.wikipedia.org
=== Do–Du === George H. Dodd (c. 1942–2020). British biochemist who studied perfumes and pheromones. Edward Adelbert Doisy (1893–1986). American biochemist at St Louis University, known for discovering vitamin K. Nobel Prize in Physiology or Medicine (1943). Ford Doolittle (b. 1942). American biochemist at Dalhousie University, known for contributions to the study of cyanobacteria and of biochemical evolution in general. Member Natl. Acad. Sci. USA. Jonathan Dordick (b. 1959). American biochemical engineer at Rensselaer Polytechnic Institute, known for development of enzyme catalysis under extreme conditions. Ralph Dorfman (1911–1985). American biochemist at Stanford, known for treatments for cancer and rheumatoid arthritis Jennifer Doudna (b. 1964). American biochemist at UC Berkeley, known for CRISPR-mediated genome editing. Member Natl. Acad. Sci. USA. Nobel Prize in Chemistry, 2020. Alexander Dounce (1909–1997). American protein chemist at the University of Rochester, active in early work on the genetic code, one of the first to suggest that it was triplet-based. Gideon Dreyfuss (PhD 1978). American biochemist and biophysicist at the University of Pennsylvania, concerned with the function and biogenesis of non-coding RNA and the proteins that interact with RNA. Member Natl. Acad. Sci. USA. Jack Cecil Drummond FRS (1891–1952). British biochemist at University College London, known for the isolation of Vitamin A, and wartime advisor on nutrition. Murdered in France, with his wife and daughter. Vincent du Vigneaud (1901–1978).
In April 2022, Kardashian and her family returned to the television screens with their brand new reality television show, titled The Kardashians, after they left the E! Network to join Hulu. The show features Kardashian, alongside her sisters Kourtney, Kim, Kendall and Kylie, and mother Kris Jenner, it also features ex and current partners including Scott Disick, Travis Barker, Kardashian's ex Tristan Thompson, and Corey Gamble, with Kanye West making a guest appearance. The first season premiered on April 14, 2022, and its ten episodes can be streamed exclusively on Disney+. Later in 2022, the show was announced to be returning for a second season, which officially premiered on September 22, 2022. In late 2022, it was announced that the show had been officially renewed for a third season, set to premier in the first half of 2023. The third season officially aired on May 25, 2023. This was followed by a fourth season in September 2023, a fifth season in May 2024, and a sixth season in February 2025. In 2024, Kardashian announced the forthcoming release of her first ever video podcast series on X. She officially launched the podcast in January 2025, titled Khloe in Wonderland and it became available on all major audio streaming services. The show is produced weekly. In April 2025, Kardashian released her own popcorn brand called Khloud by Khloe Kardashian.
=== Virology === Lagevrio (molnupiravir) ($0.9 billion in 2024 revenues) is an antiviral pill to treat COVID-19. Isentress (raltegravir) ($0.4 billion in 2024 revenues) is a human immunodeficiency virus integrase inhibitor for the treatment of HIV infection. It is the first anti-HIV compound having this mechanism of action. It is part of one of several first line treatment regimens recommended by the United States Department of Health and Human Services. Delstrigo (doravirine/lamivudine/tenofovir) ($0.3 billion in 2024 revenues) is used for the treatment of HIV/AIDS.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.